Evaluation Of Using Botulinum Toxin (A) In The Treatment Of Myofascial Pain Syndrome | 53839
ISSN: 2167-0846

Journal of Pain & Relief
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Evaluation of using botulinum toxin (A) in the treatment of myofascial pain syndrome

International Conference on Pain Research & Management

Ali El Deeb

Tanta University, Egypt

ScientificTracks Abstracts: J Pain Relief

DOI: 10.4172/2167-0846.C1.011

Myofascial pain syndrome (MPS) is a disorder which has become a topic over the past two decades and now. 10 patients (9 female and 1 male) complaining of unilateral MPS were injected with botulinum toxin type A (BTX-A) in masseter and temporalis muscles extra orally under electromyographic guidance (EMG), since they are the primary muscles responsible for pain in ear region and temporal headache, respectively, which cause limitation of mandibular movement and development of MPS. EMG evaluations of the results together with clinical one were taken at baseline before injection, after 1, 2, 3 and 6 months following the last injection. The study revealed that BTX-A reduced the severity of symptoms and improve functional abilities for patients with MPS and these extend beyond its muscle relaxing effects.

Ali El Deeb has completed his MD from Tanta University and Post-doctoral studies from Tanta University, Faculty of Medicine. He is the Supervisor of Physical Medicine, Rheumatology and Rehabilitation in new Tanta University Hospital. He is also a Reviewer for Tanta Medical Journal. He has published many papers in the reputed.

Email: [email protected]